Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Glycopyrrolate inhaled - Pearl Therapeutics

Next Previous
Drug Profile

Glycopyrrolate inhaled - Pearl Therapeutics

Alternative Names: GP MDI; PT-001; PT001 GP

Latest Information Update: 28 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pearl Therapeutics
  • Class Antiasthmatics; Antispasmodics; Antiulcers; Pyrrolidines; Quaternary ammonium compounds; Skin disorder therapies; Small molecules
  • Mechanism of Action Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 14 Apr 2026 Phase-III clinical trials in Asthma (In children, Adjunctive treatment) in USA (Inhalation) (NCT07525375)
  • 23 Feb 2021 Glycopyrrolate inhaled is still in phase II/III trial for Asthma (In adolescents, In adults, In children, In the elderly, Treatment-experienced) in USA (Inhalation) (NCT03547466)
  • 12 Sep 2019 Pearl Therapeutics completes a phase II/III trial in Asthma (In adolescents, In adults, In children, In the elderly, Treatment-experienced) in USA (Inhalation) (NCT03358147)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top